Biotech · Private company
Telios Pharma, Inc.
Track this companyFree. Adds Telios Pharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials123 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- KRT-232Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- NavtemadlinPhase 2 · Relapsed/Refractory B Cell MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- RuxolitinibPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- TL-895Phase 2 · Relapsed/Refractory B Cell MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- TL-895Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- TL-895Phase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
- TL-925Phase 2 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- TL-925Phase 2 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- TL-895Phase 1 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- Evaluation of TL-925 for the Treatment of Seasonal Allergic ConjunctivitisPHASE2 · RECRUITING · started Oct 23, 2025ClinicalTrials.gov NCT07220408 · fetched Nov 12, 2026
- Evaluation of TL-925 for the Treatment of Allergic ConjunctivitisPHASE2 · RECRUITING · started Oct 3, 2024ClinicalTrials.gov NCT06686472 · fetched Nov 12, 2026
- A Study Of TL-925 For The Treatment of ACPHASE2 · COMPLETED · started Apr 11, 2024ClinicalTrials.gov NCT06293820 · fetched Nov 12, 2026
- A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye DiseasePHASE2 · UNKNOWN · started Feb 6, 2024ClinicalTrials.gov NCT06225973 · fetched Nov 12, 2026
- A Study of TL-925 for the Treatment of Allergic ConjunctivitisPHASE2 · UNKNOWN · started Nov 1, 2023ClinicalTrials.gov NCT06153342 · fetched Nov 12, 2026
- A Study of TL-925 as a Treatment for Dry Eye DiseasePHASE2 · COMPLETED · started Feb 27, 2023ClinicalTrials.gov NCT05745064 · fetched Nov 12, 2026
- Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibPHASE1_PHASE2 · RECRUITING · started Jun 9, 2022ClinicalTrials.gov NCT05280509 · fetched Nov 12, 2026
- TL-895 and KRT-232 Study in Acute Myeloid LeukemiaPHASE1_PHASE2 · UNKNOWN · started Mar 31, 2021ClinicalTrials.gov NCT04669067 · fetched Nov 12, 2026
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFPHASE1_PHASE2 · UNKNOWN · started Nov 17, 2020ClinicalTrials.gov NCT04640532 · fetched Nov 12, 2026
- Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisPHASE2 · UNKNOWN · started Oct 22, 2020ClinicalTrials.gov NCT04655118 · fetched Nov 12, 2026
- A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With CancerPHASE1 · COMPLETED · started Jul 9, 2020ClinicalTrials.gov NCT04419623 · fetched Nov 12, 2026
- Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL SubjectsPHASE1_PHASE2 · UNKNOWN · started Aug 26, 2016ClinicalTrials.gov NCT02825836 · fetched Nov 12, 2026